DC3 Therapeutics

DC3 Therapeutics is a scientist-founded CRO based in San Diego, built to address common industry frustrations with data quality, timeliness, and impersonal client relationships. It offers an extensive suite of services spanning discovery, optimization, preclinical development, candidate selection, and regulatory support, including biomarker assay development in its CLIA lab. The company's model emphasizes deep collaboration, acting as an extension of a client's R&D team to deliver actionable insights for efficient decision-making. Its value proposition centers on scientific expertise, operational excellence, and a partnership approach to accelerate drug development.

Integrated CRO service platform with a CLIA-certified laboratory, offering a comprehensive suite from discovery to IND-enabling studies, including cell/molecular biology, biochemical assays, protein chemistry, IHC/spatial biology, and in vitro/in vivo support. Emphasizes flexible, custom assay development, GLP-like documentation, and digital pathology within a partnership model.

DC3 competes in the fragmented pre-clinical CRO market against giants like Charles River Laboratories and LabCorp, as well as numerous niche specialists. Its differentiation is a scientist-led, collaborative partnership model and integrated service offering from discovery to clinical support, targeting clients dissatisfied with impersonal, transactional CRO relationships. Success hinges on outperforming competitors on service quality, scientific insight, and flexibility.